Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 192M | 197M | 185M | 165M | 139M |
| Gross Profit | 137M | 139M | 127M | 110M | 91M |
| Operating Income | 36M | 32M | 29M | -61M | 35M |
| EBITDA | 39M | 16M | 40M | 8M | 36M |
| Net Income | 27M | 3M | 3M | -969K | 33M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.61
+18.38% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
biote Corp. (BTMDW) is a Healthcare stock with a market cap of $292.88M. The stock last traded around $1.61. Baseline metrics include revenue growth of -2.5%, EPS growth of +833.8%, a dividend yield of 0.0%. What stands out right now is revenue -2.5%, EPS +833.8%, free cash flow -22.2% with operating margin 18.5% and ROIC 43.0%. Valuation is more restrained than many high-expectation growth names at P/E 2.5 and price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines BTMDW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BTMDW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BTMDW Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BTMDW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$139.4M
-15.5% YoY
FY Net Income
$32.6M
+3466.3% YoY
Free Cash Flow
$29.9M
+372.1% YoY
Revenue Growth
-2.5%
EPS Growth
+833.8%
Gross Margin
71.5%
Net Margin
14.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 192M | 197M | 185M | 165M | 139M |
| Gross Profit | 137M | 139M | 127M | 110M | 91M |
| Operating Income | 36M | 32M | 29M | -61M | 35M |
| EBITDA | 39M | 16M | 40M | 8M | 36M |
| Net Income | 27M | 3M | 3M | -969K | 33M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 24M | 39M | 89M | 79M | 27M |
| Total Assets | 108M | 122M | 155M | 112M | 54M |
| Total Liabilities | 158M | 225M | 192M | 170M | 50M |
| Shareholder Equity | -59M | -106M | -29M | -44M | 4M |
| Total Debt | 110M | 111M | 115M | 120M | 37M |
| Net Debt | 86M | 72M | 26M | 41M | 11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
34M
+468.2% YoY
Capital Expenditures
4M
-107.1% YoY
Free Cash Flow
30M
+372.1% YoY
Key ratios
Gross Margin
71.5%
Operating Margin
18.5%
Net Margin
14.1%
ROE
-35.3%
Debt / Equity
-1.88x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.